Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TETON-PPF phase 3 inhaled treprostinil study in progressive pulmonary fibrosis
2023-504904-26-00Phase 3Authorised
- Sponsor
- United Therapeutics Corporation
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis (PF) comparing Inhaled treprostinil with Placebo nebuliser solution (2 arms). Primary endpoint: Change in absolute forced vital capacity from baseline to Week 52. Planned start Apr 2025; status: authorised.
02
Drugs
treprostinil
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2023-504904-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504904-26-00.